Clinical and research tests for C1833921 - Genetic Testing Registry (GTR) - NCBI

Warning: The NCBI web site requires JavaScript to function. more...

<< First< Prev

Page 1 of 5

Results: 1 to 20 of 96

Tests names and labs	Conditions	Genes, analytes, and microbes	Methods
Multiple Endoctine Neoplasia Type 2 (RET) Molecular Genetics Laboratory London Health Sciences Centre Canada	5	1	D Deletion/duplication analysis C Sequence analysis of the entire coding region
OnkoRisk Hereditary Oncology Plus Panel BioReference Health United States	97	77	C Sequence analysis of the entire coding region
OnkoRisk Hereditary Oncology Guideline Panel BioReference Health United States	71	54	C Sequence analysis of the entire coding region
Otogenetics Hereditary Cancers Otogenetics United States	36	39	E Sequence analysis of select exons
Hereditary Thyroid Cancer - RET Gene Analysis GeneKor MSA Greece	4	1	E Sequence analysis of select exons
Invitae Expanded Renal Disease Panel Labcorp Genetics (formerly Invitae) LabCorp United States	693	388	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Common Hereditary Cancer Screening Panel PreventionGenetics, part of Exact Sciences United States	94	55	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
myRisk Hereditary Cancer Myriad Genetics, Inc. United States	32	46	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoCancer Centogene AG - the Rare Disease Company Germany	113	68	D Deletion/duplication analysis C Sequence analysis of the entire coding region
CentoCancer Comprehensive Centogene AG - the Rare Disease Company Germany	155	107	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Solid Tumor Panel Centogene AG - the Rare Disease Company Germany	218	135	C Sequence analysis of the entire coding region
RET - MLPA Centogene AG - the Rare Disease Company Germany	5	1	D Deletion/duplication analysis
RET - NGS including CNV analysis Centogene AG - the Rare Disease Company Germany	5	1	D Deletion/duplication analysis C Sequence analysis of the entire coding region
Invitae Congenital Anomalies of Kidney and Urinary Tract (CAKUT) Panel Labcorp Genetics (formerly Invitae) LabCorp United States	67	41	D Deletion/duplication analysis
Invitae Hypopigmentation Panel Labcorp Genetics (formerly Invitae) LabCorp United States	83	46	D Deletion/duplication analysis
Stroke, Cerebral Hemorrhage, Hemiplegia, and Migraine Panel PreventionGenetics, part of Exact Sciences United States	346	160	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
Congenital Anomalies of the Gastrointestinal Tract Panel PreventionGenetics, part of Exact Sciences United States	297	180	D Deletion/duplication analysis C Sequence analysis of the entire coding region T Targeted variant analysis
Medullary thyroid carcinoma, familial, 155240, Autosomal dominant; MTC (Familial medullary thyroid carcinoma) (NTRK1 gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	C Sequence analysis of the entire coding region
Medullary thyroid carcinoma, 155240, Autosomal dominant (Multiple endocrine neoplasia type 2) (MLPA) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	D Deletion/duplication analysis
Medullary thyroid carcinoma, 155240, Autosomal dominant (Multiple endocrine neoplasia type 2) (RET gene) (Sequence Analysis-All Coding Exons) (Postnatal) Intergen Intergen Genetics and Rare Diseases Diagnosis Center Turkey	1	1	C Sequence analysis of the entire coding region

<< First< Prev

Page 1 of 5

Results: 1 to 20 of 96

IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.